Nicoderm patch first, then Aveva patch — Competitive Intelligence Brief

Nicoderm patch first, then Aveva patch (Nicoderm patch first, then Aveva patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotine replacement therapy Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicoderm patch first, then Aveva patch (Nicoderm patch first, then Aveva patch) — University of Maryland, Baltimore. A sequential nicotine replacement therapy regimen using transdermal patches to deliver nicotine and support smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicoderm patch first, then Aveva patch TARGET	Nicoderm patch first, then Aveva patch	University of Maryland, Baltimore	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Chantix	Varenicline Tartrate	Pfizer Inc.	marketed	Nicotinic receptor partial agonist	α4β2 neuronal nicotinic acetylcholine receptors
NRT (NicoDerm CQ)	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Galantamine (Reminyl)	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
bupropion + nicotine gum	bupropion + nicotine gum	University of Wisconsin, Madison	marketed	Combination smoking cessation therapy (antidepressant + nicotine replacement)	Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
patch + lozenge	patch + lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
NicoDerm CQ Patch	NicoDerm CQ Patch	Chrono Therapeutics, Inc.	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2035-10-19 — Chantix · 11224598 · Method of Use · US
• 2035-10-19 — Chantix · 10456396 · Formulation · US
• 2035-10-19 — Chantix · 9597284 · Method of Use · US
• 2035-10-19 — Chantix · 9532944 · Method of Use · US
• 2035-10-19 — Chantix · 9504644 · Method of Use · US
• 2035-10-19 — Chantix · 11911380 · Method of Use · US
• 2035-10-19 — Chantix · 11903943 · Method of Use · US
• 2035-10-19 — Chantix · 11903941 · Method of Use · US
• 2035-10-19 — Chantix · 9504645 · Formulation · US
• 2035-10-19 — Chantix · 11903942 · Formulation · US

Sponsor landscape (Nicotine replacement therapy class)

1. University of Wisconsin, Madison · 2 drugs in this class
2. Iowa City Veterans Affairs Medical Center · 1 drug in this class
3. Massachusetts General Hospital · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. University of Hawaii · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Vermont · 1 drug in this class
9. Ottawa Heart Institute Research Corporation · 1 drug in this class